The Operations Team at Outlook Therapeutics is responsible for ensuring the seamless production, compliance, and delivery of ONS-5010 / LYTENAVA™ (bevacizumab-vikg). This includes overseeing manufacturing processes, supply chain management, quality assurance, and commercial operations to support the successful development and market introduction of the ophthalmic formulation for retinal diseases.